Display options
Cite
Ferrari R, Cardoso J, Fonseca MC, et al. ARNIs: balancing "the good and the bad" of neuroendocrine response to HF. Clin Res Cardiol. 2019;109(5):599-610doi: 10.1007/s00392-019-01547-2.
Ferrari, R., Cardoso, J., Fonseca, M. C., Aguiar, C., Moreira, J. I., Fucili, A., Rapezzi, C. (2020). ARNIs: balancing "the good and the bad" of neuroendocrine response to HF. Clinical research in cardiology : official journal of the German Cardiac Society, 109(5), 599-610. https://doi.org/10.1007/s00392-019-01547-2
Ferrari, Roberto, et al. "ARNIs: balancing "the good and the bad" of neuroendocrine response to HF." Clinical research in cardiology : official journal of the German Cardiac Society vol. 109,5 (2020): 599-610. doi: https://doi.org/10.1007/s00392-019-01547-2
Ferrari R, Cardoso J, Fonseca MC, Aguiar C, Moreira JI, Fucili A, Rapezzi C. ARNIs: balancing "the good and the bad" of neuroendocrine response to HF. Clin Res Cardiol. 2020 May;109(5):599-610. doi: 10.1007/s00392-019-01547-2. Epub 2019 Sep 17. PMID: 31531687.
Copy Download .nbib Format: NLM
Share it on

Clin Res Cardiol. 2020 May;109(5):599-610. doi: 10.1007/s00392-019-01547-2. Epub 2019 Sep 17.

ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.

Clinical research in cardiology : official journal of the German Cardiac Society

Roberto Ferrari, J Cardoso, M C Fonseca, C Aguiar, J I Moreira, A Fucili, C Rapezzi,

Affiliations

  1. University Cardiologic Centre, University Hospital of Ferrara, Ferrara, Italy. [email protected].
  2. Maria Cecilia Hospital, Cotignola, Italy. [email protected].
  3. Azienda Ospedaliero-Universitaria di Ferrara, Ospedale di Cona, Via Aldo Moro 8, Cona, 44124, Ferrara, Italy. [email protected].
  4. CINTESIS-Center for Health Technology and Services Research, Porto, Portugal.
  5. Department of Cardiology, Faculty of Medicine, University of Porto, Porto, Portugal.
  6. São João Medical Centre, Porto, Portugal.
  7. Heart Failure Clinic, Hospital São Francisco Xavier, CHLO, Lisbon, Portugal.
  8. NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
  9. Advanced Heart Failure Unit, Hospital Santa Cruz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
  10. CHTMAD, Hospital S. Pedro, Vila Real, Portugal.
  11. University Cardiologic Centre, University Hospital of Ferrara, Ferrara, Italy.
  12. Cardiology, DIMES, Alma Mater-University of Bologna, Bologna, Italy.

PMID: 31531687 DOI: 10.1007/s00392-019-01547-2

Abstract

BACKGROUND: A new class of drugs-angiotensin receptor, neprylisin inhibitors, ARNI-has shown to be prognostic superior in HFrEF to the sole inhibition of the renin-angiotensin axes with enalapril. The ultimate mechanism of action of ARNIs is unknown.

AIM: We have considered that ARNI exerts a positive modulation of the neuroendocrine balance, with enhancement of the physiological diuresis and dilatation due to neprylisin inhibition by sacubitril. This represents a shift in HF medical therapy always directed to counteract (with inhibitors of the renin-angiotensin system, beta blockers or inhibitors of aldosterone) the so-called "bad" neuroendocrine response. Development of ARNI, on the contrary, has led to consider the neuroendocrine response to HFrEF from a different angle, which is to say that the activation is not always deleterious, but it could also be beneficial. This concept is highlighted by the enhancement of the activity of atrial natriuretic peptide, induced by sacubitril/valsartan in the PARADIGM trial, and found as proof from early studies on untreated patients with constrictive pericarditis. The possibility that sacubitril inhibition of neprylisin acts by enhancing substance P and gene-related calcitonin peptide is also considered, as well as the negative effect of neprylisin inhibition.

CONCLUSIONS: The beneficial effects of ARNI are related, in part at least, to a positive modulation of the neuroendocrine response to the disease, resulting in an increase of physiological diuresis and dilatation.

Keywords: ARNI; HF; Sacubitril; Valsartan

References

  1. Clin Res Cardiol. 2020 Feb;109(2):194-204 - PubMed
  2. N Engl J Med. 2019 Feb 7;380(6):539-548 - PubMed
  3. Circulation. 2002 Aug 20;106(8):920-6 - PubMed
  4. Clin Res Cardiol. 2019 Dec;108(12):1313-1323 - PubMed
  5. Am Heart J. 1989 Sep;118(3):500-5 - PubMed
  6. Am J Physiol Gastrointest Liver Physiol. 2001 Aug;281(2):G544-51 - PubMed
  7. Circulation. 2015 Jan 6;131(1):54-61 - PubMed
  8. J Mol Cell Cardiol. 1987 Mar;19(3):217-20 - PubMed
  9. Am Rev Respir Dis. 1991 Mar;143(3 Pt 2):S33-6 - PubMed
  10. Lancet. 1988 May 7;1(8593):1036-8 - PubMed
  11. Eur J Heart Fail. 2013 Sep;15(9):1062-73 - PubMed
  12. Nature. 1989 Aug 31;340(6236):721-4 - PubMed
  13. Front Aging Neurosci. 2013 Dec 23;5:98 - PubMed
  14. Nat Genet. 2013 Dec;45(12):1452-8 - PubMed
  15. Eur Heart J. 2015 Apr 14;36(15):902-5 - PubMed
  16. J Am Coll Cardiol. 2016 Aug 9;68(6):639-653 - PubMed
  17. Clin Chem. 1989 Feb;35(2):331-2 - PubMed
  18. Eur Heart J. 2015 Oct 7;36(38):2576-84 - PubMed
  19. Eur Heart J. 2016 Jul 14;37(27):2129-2200 - PubMed
  20. J Biol Chem. 2006 Oct 13;281(41):30471-8 - PubMed
  21. Cardiology. 2016;135(2):68-76 - PubMed
  22. Neuroscience. 1985 Mar;14(3):947-54 - PubMed
  23. Circulation. 1992 Jul;86(1):12-21 - PubMed
  24. J Am Coll Cardiol. 2017 Aug 8;70(6):776-803 - PubMed
  25. J Endocrinol. 2000 Nov;167(2):239-46 - PubMed
  26. Lancet. 1992 Jul 11;340(8811):88-92 - PubMed
  27. Clin Sci (Lond). 1998 Nov;95(5):547-55 - PubMed
  28. Clin Chim Acta. 2004 Feb;340(1-2):163-72 - PubMed
  29. FEBS J. 2011 Jun;278(11):1808-17 - PubMed
  30. Lancet. 2000 Aug 19;356(9230):608-9 - PubMed
  31. JACC Heart Fail. 2018 Jun;6(6):489-498 - PubMed
  32. Surgery. 2000 Aug;128(2):232-9 - PubMed
  33. Clin Res Cardiol. 2019 Oct;108(10):1074-1082 - PubMed
  34. Clin Res Cardiol. 2019 Oct;108(10):1128-1139 - PubMed
  35. Lancet Diabetes Endocrinol. 2018 Jul;6(7):547-554 - PubMed
  36. Circulation. 1989 Aug;80(2):299-305 - PubMed
  37. Clin Res Cardiol. 2019 Nov;108(11):1240-1248 - PubMed
  38. Cardiovasc Res. 1990 Nov;24(11):938-45 - PubMed
  39. Eur J Heart Fail. 2016 Sep;18(9):1193-202 - PubMed
  40. Nat Rev Cardiol. 2014 Jun;11(6):315-6 - PubMed
  41. Neurosci Lett. 1985 Jun 4;57(1):91-5 - PubMed
  42. Pharmacol Rev. 1993 Mar;45(1):87-146 - PubMed
  43. Clin Res Cardiol. 2020 Jan;109(1):22-33 - PubMed
  44. J Am Coll Cardiol. 2005 Jun 7;45(11):1900-2 - PubMed
  45. Circulation. 1991 Jun;83(6):1880-7 - PubMed
  46. N Engl J Med. 2014 Sep 11;371(11):993-1004 - PubMed
  47. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340 - PubMed
  48. J Am Coll Cardiol. 1991 Jan;17(1):208-17 - PubMed
  49. Biochem Pharmacol. 1990 Apr 15;39(8):1353-6 - PubMed

Substances

MeSH terms

Publication Types